MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

AI-Powered Chest X-Ray Triage Solution Reduces Time-to-Diagnosis of Emergency Cases

By MedImaging International staff writers
Posted on 11 Dec 2023
Print article
Image: The BraveCX AI-powered chest X-Ray triage solution has received FDA 510(k) clearance (Photo courtesy of Bering)
Image: The BraveCX AI-powered chest X-Ray triage solution has received FDA 510(k) clearance (Photo courtesy of Bering)

An AI-driven chest X-ray (CXR) triage tool has been designed to rapidly triage and prioritize critical conditions like pleural effusion and pneumothorax right after the imaging process. This technology rapidly informs physicians of its findings, acting as a supplementary "second opinion" and accelerating the diagnostic process for urgent cases.

Developed by Bering Limited (London, UK), BraveCX is an advanced radiological computer-assisted triage and notification software. It meticulously examines adult CXR images to detect the presence of certain pre-identified clinical indicators. This sophisticated tool was perfected using a vast dataset of over 1,000,000 CXRs from various clinical environments, and its precision was further enhanced with an additional 50,000 CXRs annotated by board-certified radiologists. BraveCX demonstrates impressive accuracy, with specificity rates ranging between 95% and 97% and Receiver Operating Characteristic Area Under the Curve (ROC AUC) scores of 0.96 for pleural effusion and 0.98 for pneumothorax.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to BraveCX, permitting Bering to offer this AI solution commercially to healthcare professionals and institutions within the United States. This clearance paves the way for Bering to expand its reach more aggressively in the US market. BraveCX is adaptable for various deployment methods, including cloud-based services, on-site installations, or integration with existing CXR hardware systems. This flexibility positions Bering to rapidly introduce this technology into the market through both new and existing collaborative partnerships.

"After over three years of research and collaboration with clinical teams, it's so exciting to see BraveCX emerge as a state-of-the-art tool that has actually 'listened to the end user'. FDA clearance means BraveCX prioritizes patient safety, whilst still delivering the most advanced Risk Stratification algorithms where they are needed the most," said Dr. Ignat Drozdov, CEO and founder of Bering.

Related Links:
Bering Limited 

Ultrasound Table
Women’s Ultrasound EA Table
New
Mobile Cath Lab
Photon F65/F80
New
Radiation Shielding
Oversize Thyroid Shield
40/80-Slice CT System
uCT 528

Print article

Channels

MRI

view channel
Image: The AI tool can help interpret and assess how well treatments are working for MS patients (Photo courtesy of Shutterstock)

AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans

Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more